109 Quotes by Scott Gottlieb

For one thing, Medicaid is an inefficient if not ineffective platform for redistributing income. It doesn't get the dollars to poor people in forms that they can best use. Dollars are laundered through healthcare benefits that people may not need. It also means propping up a lot of healthcare interests rather than individual Americans.

Obamacare's costly regulations mean that the mix of people who sign up are tending to be older and sicker. Many young and otherwise healthy individuals continue to be priced out of the exchanges, even after the benefit of federal subsidies are baked into their costs.

Printing novel DNA might open the way to achievements once only conceivable in science fiction: designer bacteria that can produce new chemicals, such as more efficient fuels, or synthetic versions of our cells that make us resistant to the effects of radiation.

In short order, Obamacare is evolving into a Medicaid marketplace. Not only in terms of the design and quality of the narrow-network plans that are being offered, but in the actual carriers that sell those policies.

Americans broadly consent to funding clinical research because they believe in the promise of medical research. But people support scientific work only if they trust that it serves societal interests, respects patient dignity and operates with guardrails.

Science offers the chance to cure debilitating and once-intractable disorders like hemophilia and sickle cell disease. But we need to make sure the ability to access these therapies, or the risk that someone can be locked out of them, doesn't widen gaps between the rich and poor.

By law and institutional culture, FDA seeks to apply a single tool to its approach to regulation - the requirement for pre-market approval. The agency is accustomed to compelling innovators to submit evidence to FDA and seek permission for marketing.

Many inherited disorders can perpetuate poverty by leading to disabilities that disrupt people's ability to work. In turn, someone's capacity to secure an effective new cure for these diseases can mean the difference between a life led productively, or one plagued by infirmity.

The convergence of information technology and biology allows scientists to translate the human genome into digital data that can accelerate diagnoses and cures.